Week of March 21st 2022 | Vol. 11, Issue 12
Events Hosted or Attended by Bourne Partners
March 21-24, 2022 - New York City, NY
May 17-19, 2022 - Philadelphia, PA
May 24-26, 2022 - New York City, NY
April 23-26, 2022 - Palm Beach, FL
June 13-16, 2022 - San Diego, CA
August 27-29, 2022 - Boston, MA
October 2022 - Charlotte, NC
Recent Transactions, Trading Comps, Market Reports, M&A Pipeline
An Overview of Transactions Within Market Sub-segments
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.
A Breakdown of Relevant Trading Multiples
This is a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.

For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table. 

Note: data reflects prior week close.
Insight Into Healthcare Related Industries
Representative Current Retained Sell-Side And Partnering Opportunities
Project Focus
Sell-side | CMO | Liquids and Semi-solids CMO headquartered in North America

Project Nucleus
Buy-side| CDMO | North American radiopharmaceutical company
Project Power Play
Buy-side | Specialty Pharma | In-license and acquire approved Rx products including legacy brands, generics, and niche launch-ready products

Project Trident
Buy-side | Generic Pharma | Manufacturing liquid generics
A Sampling of Industry Headlines From Last Week
With a new $987 million fund, Frazier Life Sciences is ready to form another four or five new biotechs over the next 12 months and bankroll early-stage investing in other nascent drug development startups.
Since the invasion of Ukraine, hundreds of companies have announced a pause or withdrawal of businesses in Russia.
Homegrown mRNA players BioNTech and CureVac have signed on to supply Germany with vaccines against future health emergencies for years to come.
With artificial intelligence being treated as the next frontier of drug discovery and cell research, efforts to fine-tune the technology are expanding, which is music to the ears of investors that see dollar signs when they hear “machine learning.”

The work of TannerGAP includes addressing medicine market withdrawal, post-clinical trial solutions, mitigating drug shortages and managing medicine supply on a Named Patient basis. Learn more from TannerGAP EVP, Maryori Alvarenga.

When demand for PPE and testing kits surged to unparalleled levels in March 2020 during the first wave of Covid-19, Tanner had to do something to help. Learn more about the development of TannerGMS (global medical supplies) and the future of medical supplies and diagnostics here.

The Tanner team will be attending several networking events in the coming weeks. Let’s connect to discuss how our organizations can improve patient lives, together.